FrancophonIA/ELRC3.0 huggingface dataset:
English: Upadacitinib is contraindicated during pregnancy (see section 4.3).
Danish: Upadacitinib er kontraindiceret under graviditet (se pkt.
English: Upadacitinib is metabolised mainly by CYP3A4.
Danish: Upadacitinib metaboliseres hovedsagelig af CYP3A4.
English: • medicines that affect your immune system (such as azathioprine, ciclosporin and tacrolimus)
Danish: • medicin med indvirkning på immunsystemet (f.eks. azathioprin, ciclosporin og tacrolimus).
English: The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100).
Danish: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10) og ikke almindelig (≥ 1/1.000 til < 1/100).
English: Tell your doctor if you get a painful swollen leg, chest pain, or shortness of breath as these can be signs of blood clots in the veins.
Danish: Sig det til lægen, hvis du får smertefuld hævelse i benet, brystsmerter eller åndenød, da det kan være tegn på blodprop i en vene (blodåre).
English: Administration of multiple 30 mg once daily doses of upadacitinib (a dose that is twice the recommended upadacitinib dose) to healthy subjects had a limited effect on midazolam (sensitive drug substrate for CYP3A) plasma exposures (26% decrease in midazolam AUC and Cmax), indicating that upadacitinib 30 mg once daily may have a weak induction effect on CYP3A.
Danish: Administration til raske forsøgspersoner af multiple doser upadacitinib på 30 mg én gang dagligt (en dosis, der er dobbelt så stor som den anbefalede upadacitinib-dosis) havde begrænset indvirkning på plasmaeksponeringen af midazolam (følsomt substrat for CYP3A) (26 % reduktion i midazolams AUC og Cmax), hvilket indikerer, at upadacitinib 30 mg én gang dagligt kan have en svag inducerende effekt på CYP3A.
English: CR DAS28-CRP <2.6 (% of patients)
Danish: CR DAS28-CRP < 2,6 (%-del af patienterne)
English: How to open the bottle
Danish: Sådan åbner du beholderen
English: In healthy volunteers, the administration of upadacitinib (immediate release formulation) resulted in a dose- and concentration-dependent inhibition of IL-6 (JAK1/JAK2) - induced STAT3 and IL-7 (JAK1/JAK3)-induced STAT5 phosphorylation in whole blood.
Danish: Hos raske forsøgspersoner resulterede administration af upadacitinib (formulering med øjeblikkelig frigivelse) i en dosis- og koncentrationsafhængig hæmning af fosforyleringen af IL-6 (JAK1/JAK2)induceret STAT3 og IL-7 (JAK1/JAK3)-induceret STAT5 i fuldblod.
English: • Guide for healthcare professionals
Danish: • Oplysningsfolder til sundhedspersoner
English: AbbVie Biopharmaceuticals GmbH Eesti filiaal Tel: +372 623 1011
Danish: AbbVie Biopharmaceuticals GmbH Eesti filiaal Sími: +372 623 1011
English: A decision must be made whether to discontinue breast-feeding or to discontinue upadacitinib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Danish: Det skal besluttes, om amning skal ophøre eller behandling med upadacitinib seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
English: Upadacitinib was administered in clinical studies up to doses equivalent in daily AUC to 60 mg prolonged-release once daily.
Danish: Upadacitinib blev administreret i kliniske studier i doser svarende til op til en daglig AUC på 60 mg én gang dagligt (depottabletter).
English: LDA DAS28-CRP ≤3.2 (% of patients)
Danish: LDA DAS28-CRP ≤ 3,2 (%-del af patienterne)
English: • medicines to treat fungal infections (such as itraconazole, posaconazole or voriconazole)
Danish: • medicin til behandling af svampeinfektioner (f.eks. itraconazol, posaconazol eller voriconazol)
English: This is because some medicines may reduce how well RINVOQ works or may increase the risk of getting side effects.
Danish: Dette er vigtigt, fordi nogen typer medicin kan forringe virkningen af RINVOQ eller øge risikoen for bivirkninger.
English: Studies in animals have shown reproductive toxicity (see section 5.3).
Danish: Dyrestudier har vist reproduktionstoksicitet (se punkt 5.3).
English: The physician educational material should contain:
Danish: Lægens informationsmateriale skal indeholde:
English: Potential for upadacitinib to affect the pharmacokinetics of other medicinal products
Danish: Upadacitinibs potentielle indvirkning på andre lægemidlers farmakokinetik
English: Patients should be screened for tuberculosis (TB) before starting upadacitinib therapy.
Danish: Patienten bør screenes for tuberkulose (TB), før behandlingen med upadacitinib iværksættes.
English: The most frequent serious infections reported with upadacitinib included pneumonia and cellulitis (see section 4.8).
Danish: De hyppigste alvorlige infektioner, der er indberettet ved anvendelse af upadacitinib, omfatter lungebetændelse og cellulitis (se pkt.
English: • A patient alert card
Danish: • Et patient kort
English: It is very important to talk to your doctor or pharmacist if you are taking any of the following:
Danish: Det er især vigtigt, at du fortæller det til lægen eller apotekspersonalet, hvis du tager et eller flere af nedenstående lægemidler:
English: Time to onset of efficacy was rapid across measures with greater responses seen as early as week 1 for ACR20.
Danish: Virkningen indtrådte hurtigt for alle mål, idet ACR20-responset var bedre og allerede sås i uge 1.
English: Patients should be monitored for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.
Danish: Patienterne bør overvåges for udvikling af tegn og symptomer på TB, også patienter, der er testet negative for latent TB-infektion, inden iværksættelse af behandlingen.
English: • you have had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism).
Danish: • hvis du har haft en blodprop i benet (dyb venetrombose) eller lungerne (lungeemboli).
English: No active metabolites have been identified for upadacitinib.
Danish: Der er ikke fundet aktive upadacitinib-metabolitter.
English: • Film coating: poly(vinyl alcohol), macrogol, talc, titanium dioxide, iron oxide red (E172), iron oxide black (E172).
Danish: • Filmovertræk: polyvinylalkohol, macrogol, talcum, titandioxid, rød jernoxid (E172), sort jernoxid (E172).
English: CDAI ≤10 (% of patients)
Danish: CDAI ≤ 10 (%-del af patienterne)
English: Renal impairment has no clinically relevant effect on upadacitinib exposure.
Danish: Nedsat nyrefunktion har ingen klinisk relevant betydning for upadacitinibs eksponering.
English: Viral reactivation
Danish: Virus-reaktivering
English: Anti-TB therapy should be considered prior to initiation of upadacitinib in patients with previously untreated latent TB or in patients with risk factors for TB infection.
Danish: Anti-TB-behandling bør overvejes inden påbegyndelse af upadacitinib hos patienter med tidligere ubehandlet latent TB eller patienter med risikofaktorer for TB-infektion.
English: RINVOQ is used to treat adults with rheumatoid arthritis.
Danish: RINVOQ anvendes til behandling af voksne med leddegigt (reumatoid artritis).
English: • medicines to treat Cushing's syndrome (such as ketoconazole)
Danish: • medicin til behandling af Cushings syndrom (f.eks. ketoconazol)
English: Tel: +40 21 529 30 35
Danish: Sími: +40 21 529 30 35
English: Upadacitinib therapy may be resumed once the infection is controlled.
Danish: Behandlingen med upadacitinib bør genoptages, når infektionen er under kontrol.
English: Upadacitinib was not mutagenic or genotoxic based on the results of in vitro and in vivo tests for gene mutations and chromosomal aberrations.
Danish: Upadacitinib var ikke mutagent eller genotoksisk i henhold til resultaterne af in vitro- og in vivo-test for genmutationer og kromosomafvigelser.
English: • you have ever had hepatitis B or C
Danish: • hvis du har haft hepatitis B eller C (leverbetændelse)
English: The risks and benefits of upadacitinib treatment should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing upadacitinib therapy in patients who develop a malignancy.
Danish: Risici og fordele ved upadacitinib bør overvejes, inden der iværksættes behandling hos patienter med en kendt malignitet (gælder ikke en velbehandlet non-melanom hudkræft (NMSC)), eller inden upadacitinib-behandling fortsættes hos patienter, der har udviklet en malignitet.
English: This is to check for a low red blood cell count (anaemia), low white blood cell count (neutropaenia or lymphopaenia), high blood fat (cholesterol) or high levels of liver enzymes.
Danish: Det er for at tjekke, om du har lavt antal røde blodlegemer (anæmi), lavt antal hvide blodlegemer (neutropeni eller lymfopeni), forhøjet kolesterol (fedtstof) i blodet eller forhøjede leverenzymer.
English: Upadacitinib plasma exposures are proportional to dose over the therapeutic dose range.
Danish: Upadacitinibs plasmaeksponering er dosisproportional over det terapeutiske dosisinterval.
English: bDMARD = biologic disease-modifying anti-rheumatic drug, CRP = C-Reactive Protein, DAS28 = Disease Activity Score 28 joints, mTSS = modified Total Sharp Score, csDMARD = conventional synthetic diseasemodifying anti-rheumatic drug, HAQ-DI = Health Assessment Questionnaire Disability Index, SF-36 PCS = Short Form (36) Health Survey (SF-36) Physical Component Score, CDAI = Clinical Disease Activity Index, FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue score, IR = inadequate responder, MTX = methotrexate, n = number randomised a. Patients were naïve to MTX or received no more than 3 weekly MTX doses b Patients had inadequate response to MTX c Patients who had an inadequate response to csDMARDs; patients with prior exposure to at most one bDMARD were eligible (up to 20% of total number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability d Patients who had an inadequate response to MTX; patients with prior exposure to at most one bDMARD (except adalimumab) were eligible (up to 20% of total study number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability e Patients who had an inadequate response or intolerance to at least one bDMARD
Danish: American College of Rheumatology-kriterierne på ≥ 20 % (eller ≥ 50 %); bDMARD = biologisk sygdomsmodificerende antireumatisk lægemiddel, CRP = C-reaktivt protein, DAS28 = sygdomsaktivitetsscore for 28 led, mTSS = modificeret total Sharp-score, csDMARD = konventionelt syntetisk sygdomsmodificerende antireumatisk lægemiddel, HAQ-DI = Health Assessment Questionnaire Disability Index (spørgeskema til vurdering af helbred og funktionsevne), SF-36 PCS = Short Form (36) Health Survey (SF-36) Physical Component Score, CDAI = klinisk sygdomsaktivitetsindeks, FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue score, UR = utilstrækkelige respondere, MTX = methotrexat, n = antal randomiserede a Patienterne var MTX-naive eller fik højst 3 ugentlige MTX-doser b Patienterne udviste utilstrækkeligt respons på MTX c Patienter, der udviste utilstrækkeligt respons på csDMARD's; patienter, der tidligere var blevet eksponeret for højst ét biologisk DMARD, var egnede (op til 20 % af det samlede antal patienter), hvis de enten var blevet begrænset eksponeret (< 3 måneder) eller var nødt til at seponere det biologisk DMARD på grund af intolerans d Patienter, der udviste utilstrækkeligt respons på MTX; patienter, der tidligere var blevet eksponeret for højst ét bDMARD (bortset fra adalimumab), var egnede (op til 20 % af det samlede antal patienter), hvis de enten var blevet begrænset eksponeret (< 3 måneder) eller var nødt til at seponere det biologiske DMARD på grund af intolerans e Patienter, der udviste utilstrækkeligt respons eller intolerans over for mindst ét biologisk DMARD
English: Upadacitinib, at exposures (based on AUC) approximately 4 and 10 times the clinical dose of 15 mg in male and female Sprague-Dawley rats, respectively, was not carcinogenic in a 2-year carcinogenicity study in Sprague-Dawley rats.
Danish: Ved eksponeringer (baseret på AUC) på ca. 4-10 gange den kliniske dosis på 15 mg hos SpragueDawley-rotter af hhv. han- og hunkøn var upadacitinib ikke karcinogent i et 2-årigt karcinogenicitetsstudie .
English: Upadacitinib had no effect on fertility in male or female rats at doses up to 50 mg/kg/day in males and 75 mg/kg/day in females in a fertility and early embryonic development study.
Danish: Upadacitinib havde ingen indvirkning på fertiliteten hos han- og hunrotter ved doser på op til 50 mg/kg/dag hos hanrotter og 75 mg/kg/dag hos hunrotter i et studie af fertilitet og tidlig fosterudvikling.
English: • To help you remember to take RINVOQ, take it at the same time every day.
Danish: • Tag RINVOQ på samme tidspunkt hver dag, så det er lettere at huske.
English: Methotrexate and pH modifying medicinal products (e.g., antacids or proton pump inhibitors) have no effect on upadacitinib plasma exposures.
Danish: Methotrexat og pH-modificerende lægemidler (f.eks. antacider eller protonpumpehæmmere) har ingen indvirkning på upadacitinibs plasmaeksponering.
English: Women of childbearing potential should be advised to use effective contraception during treatment and for 4 weeks following the final dose of upadacitinib.
Danish: Kvinder, der kan blive gravide, bør have at vide, at de skal bruge sikker prævention under behandlingen og i 4 uger efter den sidste dosis upadacitinib.
English: Mean CPK values increased by 4 weeks with a mean increase of 60 U/L at 12 weeks and then remained stable at an increased value thereafter including with extended therapy.
Danish: De gennemsnitlige kreatininfosfokinaseværdier steg efter 4 uger, idet der sås en gennemsnitlig stigning på 60 E/l efter 12 uger, hvorefter de forhøjede værdier forblev på et stabilt niveau, også ved længerevarende behandling.
English: Animal studies do not indicate effects with respect to fertility (see section 5.3).
Danish: Dyrestudier tyder ikke på skadevirkninger, hvad angår fertiliteten (se pkt.
English: Patients who were positive for hepatitis B surface antigen or hepatitis B virus DNA were excluded from clinical studies.
Danish: Patienter, der testede positive for hepatitis B-overfladeantigen eller hepatitis B-virus DNA, blev ekskluderet fra kliniske studier.
English: If you take more RINVOQ than you should, contact your doctor.
Danish: Hvis du har taget for meget RINVOQ, skal du kontakte lægen.
English: Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin and phenytoin), which may lead to reduced therapeutic effect of upadacitinib.
Danish: Upadacitinib-eksponeringen reduceres ved samtidig administration af stærke CYP3A4-inducere (f.eks. rifampicin og phenytoin), og det kan føre til nedsat terapeutisk effekt af upadacitinib.
English: If increases in ALT or AST are observed during routine patient management and drug-induced liver injury is suspected, upadacitinib therapy should be interrupted until this diagnosis is excluded.
Danish: Hvis der ses forhøjet ALAT eller ASAT ved den rutinemæssige patientbehandling, og hvis der er mistanke om lægemiddelinduceret leverskade, bør upadacitinib-behandlingen afbrydes, indtil denne diagnose er udelukket.
English: Consider alternatives to strong CYP3A4 inhibitor medications when used in the long-term.
Danish: Overvej alternativer til stærke CYP3A4hæmmere ved længerevarende behandling.
English: The pharmacokinetics of upadacitinib have not yet been evaluated in a paediatric population (see section 4.2).
Danish: Upadacitinibs farmakokinetik er endnu ikke undersøgt hos en pædiatrisk population (se pkt.
English: • medicines to treat bacterial infections (such as clarithromycin)
Danish: • medicin til behandling af bakterieinfektioner (f.eks. clarithromycin)
English: The most common serious adverse reactions were serious infections (see section 4.4).
Danish: De hyppigste alvorlige bivirkninger er alvorlige infektioner (se pkt.
English: If a patient develops herpes zoster, interruption of upadacitinib therapy should be considered until the episode resolves.
Danish: Hvis en patient udvikler herpes zoster, bør det overvejes at afbryde upadacitinib-behandlingen, indtil episoden har fortaget sig.
English: Contents of the pack and other information What RINVOQ contains
Danish: Pakningsstørrelser og yderligere oplysninger Rinvoq indeholder:
English: In the studies SELECT-MONOTHERAPY, SELECT-NEXT, and SELECT-COMPARE, treatment with upadacitinib 15 mg resulted in a significantly greater improvement in the mean duration of morning joint stiffness compared to placebo or MTX.
Danish: I studierne SELECT-MONOTHERAPY, SELECT-NEXT, og SELECT-COMPARE gav behandling med upadacitinib 15 mg en signifikant større bedring, hvad angår den gennemsnitlige varighed af ledstivhed om morgenen, sammenholdt med placebo eller MTX.
English: Treatment with upadacitinib 15 mg, alone or in combination with csDMARDs, resulted in improvements in individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment and hsCRP.
Danish: Behandling med upadacitinib 15 mg, alene eller i kombination med csDMARD's, resulterede i forbedringer i individuelle ACR-komponenter, herunder antallet af ømme og hævede led, samlede patient- og lægevurderinger, HAQ-DI, smertevurdering og hsCRP.
English: Laboratory measures and monitoring guidance Laboratory measure
Danish: Tabel 1: Laboratoriemålinger og monitoreringsvejledning Laboratoriemåling
English: • Clinical remission (DAS28-CRP)
Danish: • Klinisk remission (DAS28-CRP)
English: Treatment group MTX
Danish: Behandlingsgruppe MTX
English: Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, posaconazole, voriconazole, and clarithromycin).
Danish: Upadacitinib-eksponeringen øges ved samtidig administration af stærke CYP3A4-hæmmere (f.eks. ketoconazol, itraconazol, posaconazol, voriconazol og clarithromycin).
English: Like all medicines, RINVOQ can cause side effects, although not everybody gets them.
Danish: Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
English: Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment has no clinically relevant effect on upadacitinib exposure.
Danish: Let nedsat leverfunktion (Child-Pugh A) og moderat nedsat leverfunktion (Child-Pugh B) har ingen klinisk relevant betydning for upadacitinibs eksponering.
English: Malignancies were observed in clinical studies of upadacitinib.
Danish: Der er set maligniter i kliniske studier med upadacitinib.
English: Abbreviations: ADA = adalimumab; HAQ-DI = Health Assessment Questionnaire Disability Index; IR = inadequate responder; MTX = methotrexate; PBO = placebo; UPA = upadacitinib a Data shown are mean b Health Assessment Questionnaire-Disability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Danish: Forkortelser: ADA = adalimumab; HAQ-DI = Health Assessment Questionnaire Disability Index (spørgeskema til vurdering af helbred og funktionsevne); UR = utilstrækkelige respondere; MTX = methotrexat; PBO = placebo; UPA = upadacitinib a De viste data er gennemsnitsværdier b Health Assessment Questionnaire-Disability Index (spørgeskema til vurdering af helbred og funktionsevne): 0 = bedst, 3 = værst; 20 spørgsmål; 8 kategorier: klæde sig på og soignering, stå op, spise, gå, personlig hygiejne, række ud efter ting, gribe fat om ting og andre aktiviteter.
English: You will need blood tests before you start taking RINVOQ, or while you are taking it.
Danish: Du skal have taget blodprøver, før du begynder at tage RINVOQ, eller mens du er i behandling.
English: RINVOQ is not recommended for use in children and adolescents under 18 years of age.
Danish: RINVOQ anbefales ikke til børn og unge under 18 år, da lægemidlet ikke er undersøgt hos denne aldersgruppe.
English: Tel: +351 (0)21 1908400
Danish: Sími: +351 (0)21 1908400
English: Polyvinylchloride/polyethylene/polychlorotrifluoroethylene - aluminium calendar blisters in packs containing 28 or 98 prolonged-release tablets, or multipacks containing 84 (3 packs of 28) prolongedrelease tablets.
Danish: Kalenderblisterpakninger af aluminium (polyvinylchlorid/polyethylen/polychlorotrifluoroethylen) i pakninger med 28 eller 98 depottabletter eller i multipakninger med 84 (3 æsker med 28) depottabletter.
English: The recommended dose of upadacitinib is 15 mg once daily.
Danish: Den anbefalede dosis upadacitinib er 15 mg én gang dagligt.
English: Upadacitinib has no or negligible influence on the ability to drive and use machines.
Danish: Upadacitinib påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
English: The frequencies of infection ADRs for upadacitinib compared to placebo were: URTI (13.5% vs 9.5%), pneumonia (0.5% vs 0.3%), herpes zoster (0.7% vs 0.2%), herpes simplex (0.8% v 0.5%), and oral candidiasis (0.4% vs. <0.1%).
Danish: Forekomsten af infektionsrelaterede bivirkninger for upadacitinib sammenholdt med placebo var som følger: Infektion i de øvre luftveje (13,5 % vs. 9,5 %), pneumoni (0,5 % vs. 0,3 %), herpes zoster (0,7 % vs. 0,2 %), herpes simplex (0,8 % vs. 0,5 %) og oral candidiasis (0,4 % vs. < 0,1 %).
English: RINVOQ 15 mg prolonged-release tablets are purple, oblong, biconvex tablets imprinted on one side with ‘a15'.
Danish: RINVOQ 15 mg-depottabletter er lilla, aflange, bikonvekse (udadbuede) tabletter præget med "a15" på den ene side.
English: Treatment with upadacitinib 15 mg resulted in significantly greater inhibition of the progression of structural joint damage compared to placebo in combination with MTX in SELECT-COMPARE and as monotherapy compared to MTX in SELECT-EARLY (Table 5).
Danish: Behandling med upadacitinib 15 mg gav signifikant større hæmning af progressionen af strukturelle ledskader sammenholdt med placebo i kombination med MTX i SELECT-COMPARE og som monoterapi sammenholdt med MTX i SELECT-EARLY (tabel 5).
English: Upadacitinib should not be used during breast-feeding.
Danish: Upadacitinib bør ikke anvendes under amning.
English: If you are breast-feeding or are planning to breast-feed, talk to your doctor before taking this medicine.
Danish: Hvis du ammer eller planlægger at amme, skal du spørge lægen til råds, før du tager dette lægemiddel.
English: SELECT BEYOND bDMARD-IR
Danish: SELECT BEYOND bDMARD-UR
English: Upadacitinib 15 mg treatment was associated with dose-dependent increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol.
Danish: Behandling med upadacitinib 15 mg var forbundet med dosisafhængige forhøjede lipidparametre, herunder total kolesterol, triglycerider, LDL-kolesterol og HDL-kolesterol.
English: AbbVie UAB Tel: +370 5 205 3023
Danish: AbbVie UAB Sími: +370 5 205 3023
English: AbbVie SIA Tel: +371 67605000
Danish: AbbVie SIA Sími: +371 67605000
English: The most commonly reported adverse drug reactions (ADRs) are upper respiratory tract infections (13.5%), nausea (3.5%), blood creatine phosphokinase (CPK) increased (2.5%) and cough (2.2%).
Danish: De hyppigst indberettede bivirkninger er infektioner i de øvre luftveje (13,5 %), kvalme (3,5 %), øget kreatinfosfokinase (CPK) i blodet (2,5 %) og hoste (2,2 %).
English: Dose related increases in foetal resorptions associated with post-implantation losses at 25 and 75 mg/kg/day in this study in rats were attributed to the developmental/teratogenic effects of upadacitinib.
Danish: Den dosisrelaterede stigning i føtale resorptioner forbundet med postimplantationstab ved 25 og 75 mg/kg/dag i dette studie hos rotter blev tilskrevet upadacitinibs teratogene effekt og dets indvirkning på udviklingen.